An increase in Gleason 6 tumour volume while on active surveillance portends a greater risk of grade re-classification with further follow-up.

We evaluated the relative risk of later grade re-classification and outcomes of patients who developed high-volume Gleason 6 prostate cancer (PCa) while on active surveillance (AS).

A prospectively maintained database was used to identify patients on AS between 1998 and 2013.

Tumour volume was assessed based on number of positive cores and proportion of core involvement. Chi-square and Fisher's exact test were used for analysis where appropriate. The primary endpoint was development of grade re-classification, defined as grade only and/or grade and volume at the event biopsy.

A total of 555 men met study inclusion criteria. Mean follow-up was 46 months. Overall, 70 patients demonstrated an increase in tumour volume at or after their second biopsy (B2). In comparison to those never experiencing volume or grade re-classification, prostate-specific antigen at diagnosis was not significantly different (p=0. 95), but median prostate volume was smaller in patients who demonstrated volume re-classification (p

While Gleason 6 PCa has a favourable natural history, it appears that AS patients who experience volume re-classification are at a substantially higher risk of developing grade re-classification. Thus, urologists should pay close attention to tumour core involvement and monitoring should be adjusted accordingly for early volume re-classification in younger men and in good health.

The Journal of urology. 2015 Sep 25 [Epub ahead of print]

Maria Komisarenko, Lih-Ming Wong, Patrick O Richard, Narhari Timilshina, Ants Toi, Andrew Evans, Alexandre Zlotta, Girish Kulkarni, Robert Hamilton, Neil Fleshner, Antonio Finelli

Department of Uro-oncology, Division of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, Canada. , Department of Urology, St Vincent's Hospital, Melbourne, Australia, Toronto, Canada. , Department of Uro-oncology, Division of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, Canada. , Department of Uro-oncology, Division of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, Canada. , Department of Uro-oncology, Division of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, Canada. , Department of Pathology, Toronto General Hospital, University of Toronto, Canada, Toronto, Canada. , Department of Uro-oncology, Division of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, Canada. , Department of Uro-oncology, Division of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, Canada. , Department of Uro-oncology, Division of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, Canada. , Department of Uro-oncology, Division of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, Canada. , Department of Uro-oncology, Division of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, Canada. 

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe